Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still’s Disease

Table 1

Clinical and laboratory features of patients enrolled at the start of canakinumab. Abbreviations: CAN: canakinumab; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; IQR: interquartile range; MAS: macrophage activation syndrome; SD: standard deviation.

Clinical features at the start of CAN
Age at disease onset (years) ()
Age at diagnosis (years) ()
Systemic pattern,	7 (77.8%)
Chronic-articular pattern	2 (22.2%)
Fever	9 (100%)
Skin rash	5 (55.6%)
Pleuritis	4 (44.4%)
Pneumonia	0 (0%)
Pericarditis	2 (22.2%)
Lymphadenopathy	4 (44.4%)
Liver involvement	3 (33.3%)
Pharyngodynia	5 (55.6%)
Myalgia	7 (77.8%)
Arthritis	6 (66.7%)
MAS	0 (0%)
Systemic Pouchot et al. score ()
Laboratory investigations at the start of CAN
Increased ferritin serum levels	5 (55.6%)
Increased leukocyte	5 (55.6%)
Increased ESR	6 (66.7%)
Increased CRP	7 (77.8%)
Increased transaminases	3 (33.3%)